Acasti Pharma (ACST)
$0.33 0.05 (13.16%)
19:56 EDT ACST Stock Quote Delayed 20 Minutes
Previous Close $0.33
Market Cap 8.45M
PE Ratio -
Volume (Avg. Vol.) 1.04M
Day's Range 0.32 - 0.38
52-Week Range 0.25 - 3.08
Dividend & Yield N/A (N/A)
ACST Stock Predictions, Articles, and Acasti Pharma News
- From InvestorPlace
- From the Web
By Thomas Niel
It doesn't look good for Acasti Pharma stock. If they plan on doubling-down on CaPre, they need more capital. A dilutive equity raise would push shares down further. Even if they do a reverse stock split. Yet, shares aren't guaranteed to hit zero. If their subsequent actions with CaPre pay off, shares could soar as the prospective drug gets back on track.
Acasti Pharma stock plunged after the company reported negative trial results. The company's road ahead is filled with risks.
Acasti Pharma stock collapsed following an unsuccessful Phase 3 clinical trial. But even this major setback isn't the only headwind impacting shares.
By Ian Cooper
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.
Acasti's Phase 3 trial of CaPre, aimed at patients with high levels of triglycerides, isn't working out, explaining why the stock is down 69.11% to start 2020. One of the primary causes of concern with the Trilogy 1 Phase 3 trial of CaPre was that there were unanticipated levels of placebo response. Said another way, patients got a cornstarch pill, which of course would be far less expensive than any drug, and had a positive reaction to it.
Acasti Pharma lost $118 million in market capitalization on January 13. That makes Acasti Pharma stock a liability, not a bargain.
Following unsuccessful Phase 3 clinical trial results for its core CaPre treatment, Acasti and ACST stock look doomed.
Acasti hopes a second study of its CaPre drug, due for release next month, shows better results, but most investors have left ACST stock.
Acasti got some bad news recently from the FDA regarding its main drug candidate. And this news could make it tough for ACST stock to recover.
When Acasti posts Phase 3 trial results, ACST stock could re-visit recent highs. Here's why you should pay attention to the stock now.
Acasti Pharma (ACST) is having trouble on Monday as ACST stock has fallen a great deal, but what's behind the falling prices?
This week, the overall grades of 10 Pharmaceuticals stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The following stocks were the biggest movers and shakers in the Manufacturing sector today.
Even in the good conditions of the biotech market today, investors should do due diligence and find reliable sources when picking biotech stocks.
From Analyst Ratings
Oppenheimer analyst Leland Gershell maintained a Buy rating on Acasti Pharma (ACST – Research Report) yesterday. The company’s shares closed last Monday at $0.38, close to its 52-week low of $0.35. According to TipRanks.com, Gershell is a 4-star analyst with an average return of 6.6% and a 38.3% success rate. Gershell covers the Healthcare sector,
Navellier RatingsPowered by Portfolio Grader